Genus (LON:GNS) Earns “Buy” Rating from Berenberg Bank

Genus (LON:GNSGet Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at Berenberg Bank in a report issued on Tuesday,London Stock Exchange reports. They currently have a GBX 3,350 target price on the stock. Berenberg Bank’s price target would suggest a potential upside of 58.17% from the stock’s current price.

Genus Stock Performance

Shares of Genus stock opened at GBX 2,118 on Tuesday. The company has a 50 day moving average of GBX 2,246.45 and a 200-day moving average of GBX 2,553.64. Genus has a 1-year low of GBX 1,943 and a 1-year high of GBX 3,220. The company has a current ratio of 2.25, a quick ratio of 1.08 and a debt-to-equity ratio of 51.73. The company has a market cap of £1.41 billion, a PE ratio of 29.83, a price-to-earnings-growth ratio of 2.87 and a beta of 0.90.

Insiders Place Their Bets

In other Genus news, insider Celia Baxter acquired 2,336 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The stock was acquired at an average cost of GBX 2,140 per share, for a total transaction of £49,990.40. Also, insider Jorgen Kokke sold 3,450 shares of the company’s stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of GBX 2,267, for a total value of £78,211.50. Company insiders own 0.71% of the company’s stock.

About Genus

(Get Free Report)

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands.

Read More

Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.